Market Access News | pharmaphorum

News

NICE backs Ocrevus for PPMS in England - but with caveats

Patients with a severe progressive form of multiple sclerosis will get access to the first licensed treatment for the condition after NICE recommended regular NHS funding for Roche's Ocrevu

News

Ionis' FCS drug approved in EU, launch due in Germany

Ionis Pharmaceuticals’ RNA-targeted drug Waylivra has been conditionally approved in Europe for the devastating ultra-rare disease Familial Chylomicronemia Syndrome (FCS).

News

Sanofi claims EU okay for Dupixent in asthma

Sanofi and partner Regeneron have picked up an approval in Europe for Dupixent in asthma, unlocking an important new indication for the fast-growing biologic.

News

Catalyst shares dive amid speculation about 'off-label' rare...

Shares in Catalyst Pharmaceuticals have dived after the US regulator approved a potential competitor to its rare disease drug Firdapse, which has been at the centre of a drug pricing row.

News

NICE recommends Roche's Tecentriq combo for certain lung can...

Certain patients with untreated lung cancer in England have a new treatment option after cost-effectiveness body NICE made a draft recommendation that the NHS should fund Roche’s cocktail i

News

UK government revamps efforts to hasten access to new drugs

The UK government has announced a major revamp of its efforts to get innovative new medicines and therapies through clinical development and to the market.

NICE backs Ocrevus for PPMS in England - but with caveats

Ionis' FCS drug approved in EU, launch due in Germany

Sanofi claims EU okay for Dupixent in asthma

Catalyst shares dive amid speculation about 'off-label' rare...

NICE recommends Roche's Tecentriq combo for certain lung can...

UK government revamps efforts to hasten access to new drugs

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks